NM
Nir Messafi Portfolio
Invests via Deep Track Capita LLP | Managed by David Kroin
Invests via Deep Track Capita LLP
Managed by David Kroin
Automatically Tracked
Nir Messafi Profile
Nir Messafi is a dynamic entrepreneurial founder with deep expertise in technology-driven startups. With a background in engineering and extensive experience in software development, he has successfully launched several innovative ventures that have redefined industry standards. His commitment to fostering disruptive technologies places him at the forefront of the digital landscape. By bridging the gap between technical innovation and market needs, he plays a crucial role in shaping emerging business models across various sectors. Messafi's ability to identify growth opportunities enables him to navigate complex market challenges, making significant contributions to entrepreneurship and investment landscapes.
Nir Messafi is a dynamic entrepreneurial founder with deep expertise in technology-driven startups. With a background in engineering and extensive experience in software development, he has successfully launched several innovative ventures that have redefined industry standards. His commitment to fostering disruptive technologies places him at the forefront of the digital landscape. By bridging the gap between technical innovation and market needs, he plays a crucial role in shaping emerging business models across various sectors. Messafi's ability to identify growth opportunities enables him to navigate complex market challenges, making significant contributions to entrepreneurship and investment landscapes.
Investment Philosophy & Strategy
With a strong focus on innovation, Nir Messafi seeks transformative opportunities within the technology sector. His entrepreneurial spirit drives him to explore nascent markets where emerging technologies can create significant impact. Capitalizing on his engineering background and software development expertise, he targets investments that promise substantial scalability and differentiation. By understanding customer demands and aligning them with groundbreaking solutions, he positions himself strategically in competitive landscapes. This approach not only fuels growth for his ventures but also contributes to redefining industry standards through operational excellence.
With a strong focus on innovation, Nir Messafi seeks transformative opportunities within the technology sector. His entrepreneurial spirit drives him to explore nascent markets where emerging technologies can create significant impact. Capitalizing on his engineering background and software development expertise, he targets investments that promise substantial scalability and differentiation. By understanding customer demands and aligning them with groundbreaking solutions, he positions himself strategically in competitive landscapes. This approach not only fuels growth for his ventures but also contributes to redefining industry standards through operational excellence.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
172.62%
Gain -3.48%
Monthly
1.65%
Yearly
21.75%
Drawdown
46.51%
$5.59B
Equity
Holdings
$5.59B
Investment
$3.66B
$2.43B
Profit -$113.98M
Realized
$501.99M
Unrealized
$1.93B
Dividends
$2.8M
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-3.48%
Profit
-$113.98M
Win %
75%
This Week
Compared To Last Week
Gain
-1.99%
Profit
-$113.7M
Win %
75%
This Month
Compared to last month
Gain
-1.27%
Profit
-$71.61M
Win %
75%
This Year
Compared to last year
Gain
24.67%
Profit
$1.11B
Win %
77%
PMN ProMIS Neurosciences, Inc.
+8.56%
+$1.09M 
VRDN Viridian Therapeutics Inc.
+4.99%
+$1.25M 
ENGN enGene Therapeutics Inc.
+2.75%
+$218,878.6 
LRMR Larimar Therapeutics Inc.
+1.76%
+$97,500 
CNTX Context Therapeutics Inc.
+1.57%
+$69,741.94 
MAZE Maze Therapeutics Inc.
+0.21%
+$208,653.72 
CYTK Cytokinetics, Incorporated
+0.21%
+$231,298.06 
CBIO Crescent Biopharma, Inc.
+0.18%
+$12,022.68 
BMRN Biomarin Pharmaceutical Inc.
+0.18%
+$120,750 
CLDX Celldex Therapeutics Inc.
+0.14%
+$64,198.95 
DYN Dyne Therapeutics Inc.
+0.11%
+$53,800 
APGE Apogee Therapeutics Inc.
+0.09%
+$32,775 
APLS Apellis Pharmaceuticals Inc.
0%
$0 
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
0%
$0 
NUVL Nuvalent, Inc.
0%
$0 
SLNO Soleno Therapeutics, Inc.
0%
$0 
TERN Terns Pharmaceuticals, Inc.
0%
$0 
PSNL Personalis Inc.
-12.96%
-$5.99M 
ALGS Aligos Therapeutics Inc.
-5.14%
-$131,012.45 
GRAL Grail, Inc.
-5.14%
-$6.43M 
MBX MBX Biosciences, Inc.
-5.04%
-$8.74M 
CMPS Compass Pathways plc Depositary Receipt
-4.86%
-$7.3M 
ENTA Enanta Pharmaceuticals Inc.
-4.51%
-$1.21M 
GH Guardant Health Inc.
-4.49%
-$23.37M 
GPCR Structure Therapeutics Inc.
-4.3%
-$8.92M 
CRVS Corvus Pharmaceuticals Inc.
-4.06%
-$1.51M 
CRMD CorMedix Inc.
-3.8%
-$2.01M 
TARS Tarsus Pharmaceuticals Inc.
-3.76%
-$8.1M 
BLLN BillionToOne, Inc.
-3.74%
-$243,500 
MANE Veradermics Inc.
-3.36%
-$1.87M 
VSTM Verastem Inc.
-3.23%
-$1.12M 
BEAM Beam Therapeutics Inc.
-3.13%
-$706,432.44 
IVA Inventiva S.A.
-2.81%
-$158,918.89 
TNGX Tango Therapeutics Inc.
-2.68%
-$2.1M 
LBRX LB Pharmaceuticals Inc.
-2.58%
-$2.72M 
XFOR X4 Pharmaceuticals Inc.
-2.49%
-$602,255.82 
OCUL Ocular Therapeutix Inc.
-2.17%
-$3.84M 
SLDB Solid Biosciences Inc.
-2.12%
-$659,536.47 
VERA Vera Therapeutics Inc.
-2.03%
-$3.2M 
IMCR Immunocore Holdings plc American Depositary Receipt
-2%
-$1.35M 
IPSC Century Therapeutics, Inc.
-2%
-$426,948.53 
GMAB Genmab A/S Sponsored ADR
-1.86%
-$1.96M 
MLTX MoonLake Immunotherapeutics
-1.65%
-$2.08M 
AXSM Axsome Therapeutics, Inc.
-1.22%
-$3.08M 
NRIX Nurix Therapeutics Inc.
-1.17%
-$1.71M 
ANIP Ani Pharmaceuticals Inc.
-1.14%
-$543,000 
PCVX Vaxcyte, Inc.
-1.13%
-$2.73M 
COGT Cogent Biosciences, Inc.
-1.13%
-$440,000 
ALKS Alkermes plc
-1.06%
-$2.01M 
DFTX Definium Therapeutics, Inc.
-1.04%
-$1.38M 
ALMS Alumis Inc.
-0.98%
-$1.9M 
ACRS Aclaris Therapeutics, Inc.
-0.97%
-$513,975 
IONS Ionis Pharmaceuticals, Inc.
-0.96%
-$1.02M 
GERN Geron Corporation
-0.84%
-$383,815.36 
JANX Janux Therapeutics Inc.
-0.68%
-$130,601.9 
ORKA Oruka Therapeutics, Inc.
-0.66%
-$1.24M 
BCAX Bicara Therapeutics Inc.
-0.63%
-$710,937.5 
IMVT Immunovant Inc.
-0.46%
-$2.12M 
ATAI AtaiBeckley Inc.
-0.42%
-$360,000 
KURA Kura Oncology Inc.
-0.28%
-$79,306.26 
BBIO BridgeBio Pharma, Inc.
-0.25%
-$168,289 
HELP Cybin Inc.
-0.03%
-$3,282.84 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 849 | Longs Won 406/849 47% | Profit Factor 2.77 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $15.31M |
| Average Win $9.37M | Best Trade (Jul 19) $199.47M | Sharpe Ratio -40.11 |
| Average Loss -$3.1M | Worst Trade (Dec 31) -$47.76M | Z-Score -1.11 (73.54%) |
| Commissions $0 | Avg. Trade Length 1y 2d | Expectancy $2.86M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 1,802 | 1,622 | 1,441 | 1,261 | 1,081 | 901 | 721 | 541 | 360 | 180 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Nir Messafi?
The largest contributions to the portfolio's profits come from the following stocks: Insmed Inc - $251.52M, Immunovant Inc - $206.44M, Ionis Pharmaceuticals, Inc - $142.19M, Guardant Health Inc - $133.87M, and Alnylam Pharmaceuticals Inc - $77.86M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Pliant Therapeutics Inc - $117.01M, Bicycle Therapeutics plc American Depositary Receipt - $88.58M, Travere Therapeutics Inc - $77.95M, Fate Therapeutics Inc - $62.41M, and 4D Molecular Therapeutics, Inc - $58.81M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Nir Messafi's portfolio generate?
The portfolio generates substantial dividend income, with a total of $2.8M earned over time. The largest contributors to dividend income include Amgen Inc - $2.8M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Nir Messafi's monthly returns?
Nir Messafi's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Nir Messafi's strategy be considered aggressive or moderate?
Nir Messafi's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Nir Messafi's strategy?
Nir Messafi's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
